Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT04966221
Other study ID # 21048
Secondary ID
Status Recruiting
Phase
First received
Last updated
Start date January 1, 2022
Est. completion date August 1, 2024

Study information

Verified date May 2022
Source University of Nottingham
Contact Jonathan Philip Brooke
Phone 01158231154
Email jonathan.brooke@nottingham.ac.uk
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

This study aims to use novel proton-based MRI techniques to assess lung function and structure in healthy volunteers and patients with chronic obstructive pulmonary disease (COPD) and alpha-1-anti-trypsin deficiency (A1ATD). These novel MRI measures will be compared to matched contemporary clinical diagnostic tools, namely pulmonary function tests (PFTs) and computed tomography (CT) scans. MRI has the advantages of avoiding ionising radiation exposure (unlike CT scans) and can also provide regional measures of lung function (unlike PFTs which provide global measures of function). In addition, these MRI techniques do not require the use of any inhaled or injected contrast agents. Some patients enrolled in this study will be undergoing a lung volume reduction (LVR) procedure as part of their normal clinical care. LVR is an intervention for patients with severe lung disease and hyperinflation. It is a palliative therapy that helps to reduce lung hyperinflation through insertion of small valves in the airway or surgical removal of parts of the lung. This can lead to improvements in symptoms such as breathlessness and improve exercise tolerance due to better functioning of the lung. In this study, we will explore how lung MRI measures can be used to assess patients before and after an LVR intervention. This study will take place at the University of Nottingham in collaboration with Nottingham University Hospitals NHS Trust. The study will last for 3 years and participants will be asked to attend a screening visit (lasting up to 1 hour) and either one or two study visits (each lasting up to 3 hours).


Description:

This is a single centre pilot study. The research team aims to recruit adult healthy volunteers and adult patient volunteers with COPD and A1ATD. We have used similar proton-based MRI techniques in healthy volunteers and people with other lung diseases and the MRI scans have been well tolerated. All participants will be adults (both male and female) who can give informed consent and are able to undertake the study procedures. Potential participants who cannot have an MRI scan for safety reasons (e.g. have a pacemaker) will not be recruited. During study visits, all research activities will be observed by a member of the research team. During the screening visit (following consent), the following information and measures will be taken: Relevant past medical history, COPD assessment tool (questionnaire), height, weight, blood pressure and pulse oximetry. During study visits, a combination of structural and functional lung MRI scans will be performed with the participant lying in the scanner. Participants will be asked to breathe normally during scans and may also be asked to perform breathing manoeuvres such as holding their breath temporarily. The participants will be assigned unique codes, and their data will be anonymised. Participants' medical reports will only be accessed for study purposes and will be treated as confidential. The investigators will aim to use the data to plan future studies, and the data from this study may contribute to publications and presentations. Participants will not be identified in any publications arising from the research. The data obtained will be published without any identifying information.


Recruitment information / eligibility

Status Recruiting
Enrollment 75
Est. completion date August 1, 2024
Est. primary completion date August 1, 2024
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years and older
Eligibility Workstream 1 Inclusion criteria (Adult Healthy Volunteers) - Male or female aged 18 years and over - Capacity to give informed consent - Normal blood pressure (systolic BP > 90 mmHg and diastolic BP >50 mmHg) - Resting heart rate > 50bpm - For women, negative urinary ß-hCG at the screening and subsequent visits (where clinical uncertainty of pregnancy) - Subject able to hold breath for 10 seconds - Subject able to understand the requirements of the study and to cooperate with the study procedures - Subject has normal lung function by spirometry criteria - Smoking history of > 10 pack years of tobacco smoking Workstream 1 Exclusion criteria (Adult Healthy Volunteers) - Unsuitable for MRI scanning (e.g. have metal implants or pacemaker or contraindicated following questionnaire) - Subject deemed unlikely to comply with instructions during imaging - Subject not deemed fit enough to tolerate procedure - Subject deemed unsuitable by clinical investigator for other reasons - Abnormal spirometry Workstream 2 Inclusion criteria (Adults with chronic obstructive pulmonary disease) - Male or female aged 18 years and over - Capacity to give informed consent - Normal blood pressure (systolic BP > 90 mmHg and diastolic BP >50 mmHg) - Resting heart rate > 50bpm - For women, negative urinary ß-hCG at the screening and subsequent visits (where clinical uncertainty of pregnancy) - Subject able to hold breath for 10 seconds - Subject able to understand the requirements of the study and to cooperate with the study procedures - Diagnosis of COPD made by respiratory physician and confirmed by spirometry criteria (FEV1/FVC ratio < 0.7) and > 10 pack years of tobacco smoking. Workstream 2 Exclusion criteria (Adults with chronic obstructive pulmonary disease) - Unsuitable for MRI scanning (e.g. have metal implants or pacemaker or contraindicated following questionnaire) - Acute illness considered to be of sufficient severity to prevent safe MRI scanning. In this instance, the subject will be invited to be rescreened > 4 weeks later. - Subject deemed unlikely to comply with instructions during imaging - Subject not deemed fit enough to tolerate procedure - Subject deemed unsuitable by clinical investigator for other reasons Workstream 3 Inclusion criteria (Adults with COPD due to alpha-1-antitrypsin deficiency - A1ATD) - Male or female aged 18 years and over - Capacity to give informed consent - Normal blood pressure (systolic BP > 90 mmHg and diastolic BP >50 mmHg) - Resting heart rate > 50bpm - For women, negative urinary ß-hCG at the screening and subsequent visits (where clinical uncertainty of pregnancy) - Subject able to hold breath for 10 seconds - Subject able to understand the requirements of the study and to cooperate with the study procedures - Diagnosis of A1ATD (PiZZ or PiZ-) and either evidence of emphysema on a previous clinical CT scan or evidence of airways obstruction Workstream 3 Exclusion criteria (Adults with COPD due to alpha-1-antitrypsin deficiency - A1ATD) - Unsuitable for MRI scanning (e.g. have metal implants or pacemaker or contraindicated following questionnaire) - Acute illness considered to be of sufficient severity to prevent safe MRI scanning. In this case, the subject will be rescreened >4 weeks later - Subject deemed unlikely to comply with instructions during imaging - Subject not deemed fit enough to tolerate procedure - Subject deemed unsuitable by clinical investigator for other reasons

Study Design


Related Conditions & MeSH terms


Intervention

Diagnostic Test:
Lung MRI scan
Participants will have a combination of structural and functional lung MRI scans. These scans will involve lying in a conventional MRI scanner while free breathing and may include additional breathing manoeuvres such as temporarily holding breath.

Locations

Country Name City State
United Kingdom Sir Peter Mansfield Imaging Centre, University of Nottingham Nottingham Nottinghamshire

Sponsors (2)

Lead Sponsor Collaborator
University of Nottingham Nottingham University Hospitals NHS Trust

Country where clinical trial is conducted

United Kingdom, 

Outcome

Type Measure Description Time frame Safety issue
Primary To acquire structural and functional proton-based lung MRI scans from patients with COPD and COPD due to A1ATD and produce baseline data for these groups to inform future clinical studies To compare functional MRI outcomes with matched clinical physiological data (e.g. pulmonary function tests) To compare structural lung images with matched conventional imaging techniques done for clinical reasons (e.g. computed tomography) of the diaphragm and lungs 3 years
Secondary To assess the ability of participants of each group to adhere to the protocols, thus informing the study design of future trials 3 years
Secondary To assess any change of MR outcomes across study visits for those participants undertaking more than one MR scanning visit. 3 years
Secondary To assess any change of MR outcomes across study visits for participants who undergo LVR 3 years
See also
  Status Clinical Trial Phase
Completed NCT05102305 - A Multi-center,Prospective, OS to Evaluate the Effectiveness of 'NAC' Nebulizer Therapy in COPD (NEWEST)
Completed NCT01867762 - An Effectiveness and Safety Study of Inhaled JNJ 49095397 (RV568) in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease Phase 2
Recruiting NCT05562037 - Stepped Care vs Center-based Cardiopulmonary Rehabilitation for Older Frail Adults Living in Rural MA N/A
Terminated NCT04921332 - Bright Light Therapy for Depression Symptoms in Adults With Cystic Fibrosis (CF) and COPD N/A
Completed NCT03089515 - Small Airway Chronic Obstructive Disease Syndrome Following Exposure to WTC Dust N/A
Completed NCT02787863 - Clinical and Immunological Efficiency of Bacterial Vaccines at Adult Patients With Bronchopulmonary Pathology Phase 4
Recruiting NCT05552833 - Pulmonary Adaptive Responses to HIIT in COPD N/A
Recruiting NCT05835492 - A Pragmatic Real-world Multicentre Observational Research Study to Explore the Clinical and Health Economic Impact of myCOPD
Recruiting NCT05631132 - May Noninvasive Mechanical Ventilation (NIV) and/or Continuous Positive Airway Pressure (CPAP) Increase the Bronchoalveolar Lavage (BAL) Salvage in Patients With Pulmonary Diseases? N/A
Completed NCT03244137 - Effects of Pulmonary Rehabilitation on Cognitive Function in Patients With Severe to Very Severe Chronic Obstructive Pulmonary Disease
Not yet recruiting NCT03282526 - Volume Parameters vs Flow Parameters in Assessment of Reversibility in Chronic Obstructive Pulmonary Disease N/A
Completed NCT02546700 - A Study to Evaluate Safety and Efficacy of Lebrikizumab in Participants With Chronic Obstructive Pulmonary Disease (COPD) Phase 2
Withdrawn NCT04446637 - Acute Bronchodilator Effects of Ipratropium/Levosalbutamol 20/50 mcg Fixed Dose Combination vs Salbutamol 100 mcg Inhaler Plus Ipratropium 20 mcg Inhalation Aerosol Free Combination in Patients With Stable COPD Phase 3
Completed NCT04535986 - A Phase 3 Clinical Trial to Evaluate the Safety and Efficacy of Ensifentrine in Patients With COPD Phase 3
Recruiting NCT05865184 - Evaluation of Home-based Sensor System to Detect Health Decompensation in Elderly Patients With History of CHF or COPD
Completed NCT03295474 - Telemonitoring in Pulmonary Rehabilitation: Feasibility and Acceptability of a Remote Pulse Oxymetry System.
Completed NCT03256695 - Evaluate the Relationship Between Use of Albuterol Multidose Dry Powder Inhaler With an eModule (eMDPI) and Exacerbations in Participants With Chronic Obstructive Pulmonary Disease (COPD) Phase 3
Withdrawn NCT04042168 - Implications of Appropriate Use of Inhalers in Chronic Obstructive Pulmonary Disease (COPD) Phase 4
Completed NCT03414541 - Safety And Efficacy Study Of Orally Administered DS102 In Patients With Chronic Obstructive Pulmonary Disease Phase 2
Completed NCT02552160 - DETECT-Register DocumEnTation and Evaluation of a COPD Combination Therapy